Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Imbruvica Leads Sea Change In CLL Landscape

This article was originally published in Scrip

Executive Summary

Johnson & Johnson/AbbVie Inc. 's Imbruvica (ibrutinib) has rapidly established itself as standard of care in relapsed/refractory chronic lymphocytic leukaemia and will increasingly move into the first-line setting following its recent approval by the FDA for that use in patients with CLL, analysts say.

You may also be interested in...

AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn

With AbbVie's next-generation HCV combo Marivet, newly approved in Europe, the company can look to it and growing sales from Imbruvica to help make up for Humira revenue losses that may start in 2018.

Novartis Withdraws Arzerra CLL Second-Line Use Filing in EU

Novartis has withdrawn its label extension application in Europe for use of Arzerra in combination with bendamustine for the treatment of relapsed chronic lymphocytic leukemia, following CHMP queries over a lack of comparable data.

Janssen Oncology Strategy: Take A Holistic Approach To R&D

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts